title: [Outcomes of surgical management of retinopathy of prematurity--an overview].
abstract: According to the guidelines by the ETROP (Early Treatment for Retinopathy of Prematurity) study group, laser therapy is the gold standard in the treatment of retinopathy of prematurity. However, progression of the disease is seen in 12% of eyes despite the treatment. Since there is no causal treatment, new therapies of retinopathy of prematurity, are continually sought, such as anti-VEGF agents, beta-blockers, or insulin-like growth factor gene therapy. In cases with concomitant retinal detachment, surgery is performed. The standard therapy for retinopathy of prematurity stages 4-5 involves pars plicata vitrectomy and lensectomy (stage 5), ab externo surgery (scleral buckling) and lens-sparing vitrectomy (some cases of stage 4). Classic vitrectomy with lensectomy is reserved only for cases with advanced retinal tractions, retina-lens apposition or for cases of intraoperative lens damage during the lens-sparing vitrectomy. The ab externo surgery does not eliminate vitreous tractions, but it stabilises the neovascular membrane activity (transforming it into a scar). The indication for this type of operation is stage 4 retinopathy of prematurity with peripheral proliferations, except for the posterior--aggressive form of retinopathy of prematurity. Many papers have been published on combined therapy involving vitrectomy and conservative treatment. In conclusion, optimal timing of surgical intervention is difficult to determine in stages 4 and 5, because the anatomical and functional outcomes in stage 5 are unfavourable. Both, ab externo surgery and vitrectomy tend to produce poor macular vision in eyes with advanced retinopathy of prematurity, therefore surgical intervention at stage 4 just before the local macular retinal detachment provides better anatomical and functional outcomes.
authors.forename: Leszek
authors.initials: L
authors.lastname: Kuprjanowicz
authors.forename: Katarzyna
authors.initials: K
authors.lastname: Kubasik-Kładna
authors.forename: Monika
authors.initials: M
authors.lastname: Modrzejewska
mesh_terms: D020533:Angiogenesis Inhibitors / Q000627:therapeutic use; D003131:Combined Modality Therapy; D003452:Cryosurgery / Q000379:methods*; D006801:Humans; D007231:Infant, Newborn; D053685:Laser Therapy / Q000379:methods*; D012163:Retinal Detachment / Q000209:etiology / Q000601:surgery*; D012178:Retinopathy of Prematurity / Q000150:complications / Q000601:surgery*; D012591:Scleral Buckling / Q000379:methods*; D014792:Visual Acuity; D014821:Vitrectomy / Q000379:methods*
chemical_list: D020533:Angiogenesis Inhibitors